Brayden Yellman, MD
Rheumatology · Murray, UTNPI 1194011841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Merck at 25.4% of the total. Reporting peaked in 2019 at $204 and has fallen 82.4% since, to $36 in 2024. That places this record below the midpoint for rheumatology clinicians in UT, where the typical reported total is $586.
Across 19 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$78
- AstraZeneca$47
- Genentech USA, Inc.$36
- Johnson & Johnson$33
- Lilly USA, LLC$25
- Novo Nordisk$23
- plus $64 from 4 others
Across 40 payments — averaging $11,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$452K
What the payments were for
- Food & beverage$306100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $78 |
| AstraZeneca | 2 | $47 |
| Genentech USA, Inc. | 1 | $36 |
| Johnson & Johnson | 2 | $33 |
| Lilly USA, LLC | 2 | $25 |
| Novo Nordisk | 2 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
How this compares
$306 in reported general payments places this provider in the 35th percentile of 52 rheumatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Droxidopa | 13 | $57,948 |
| Cromolyn Sodium | 77 | $20,718 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 44 | $20,143 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,932 |
| Midodrine Hcl | 104 | $7,586 |
| Pyridostigmine Bromide | 55 | $6,105 |
| Sirolimus | 29 | $4,327 |
| Famciclovir | 40 | $3,642 |
| Lidocaine | 15 | $3,401 |
| Aripiprazole | 79 | $3,356 |
| ValacyclovirValacyclovir Hcl | 38 | $2,434 |
| Zolpidem Tartrate | 48 | $2,007 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,987 |
| Lisdexamfetamine Dimesylate | 11 | $1,937 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $1,795 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Murray
- Seung Yoon LeeMurray$22K
- Dany SaadMurray$913
- Danette KoMurray$614
- Sonia GuptaMurray$596
- Don StromquistMurray$0
- Catherine BakewellSalt Lake City$1M
- Jessica WalshSlc$162K
- Shruti SanghviVineyard$63K
- Curry KoeningSalt Lake City$59K
- Carmen GotaSt. George$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.